Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...
Morgan Stanley analyst Terence Flynn has maintained their neutral stance on MRK stock, giving a Hold rating yesterday.Invest with Confidence: ...
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of ...
Zacks.com on MSN2d
Merck Halts Second PAH Drug Study Early on Strong Efficacy ResultsMerck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...
Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...
All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback